

AurÃ©lie Barrail-Tran

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5293074/publications.pdf>

Version: 2024-02-01

30
papers

499
citations

686830

13
h-index

676716

22
g-index

32
all docs

32
docs citations

32
times ranked

956
citing authors

#	ARTICLE	IF	CITATIONS
1	Drug-Drug Interactions Between HMG-CoA Reductase Inhibitors (Statins) and Antiviral Protease Inhibitors. <i>Clinical Pharmacokinetics</i> , 2013, 52, 815-831.	1.6	116
2	Randomised Pharmacokinetic Trial of Rifabutin with Lopinavir/Ritonavir-Antiretroviral Therapy in Patients with HIV-Associated Tuberculosis in Vietnam. <i>PLoS ONE</i> , 2014, 9, e84866.	1.1	38
3	Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia. <i>Aids</i> , 2011, 25, 665-669.	1.0	33
4	Adherence Profiles and Therapeutic Responses of Treatment-Naive HIV-Infected Patients Starting Boosted Atazanavir-Based Therapy in the ANRS 134-COPHAR 3 Trial. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2265-2271.	1.4	31
5	Pharmacokinetics of Phase I Nevirapine Metabolites following a Single Dose and at Steady State. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2154-2160.	1.4	31
6	A 2.5-Year Within-Patient Evolution of <i>Pseudomonas aeruginosa</i> Isolates with In Vivo Acquisition of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Resistance upon Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	26
7	Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 515-524.	1.1	25
8	Nevirapine or efavirenz for tuberculosis and HIV coinfecting patients: exposure and virological failure relationship*. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 225-232.	1.3	24
9	Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients. <i>Liver Transplantation</i> , 2011, 17, 1152-1158.	1.3	18
10	Characterization of Binding of Raltegravir to Plasma Proteins. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5147-5150.	1.4	17
11	Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients. <i>Aids</i> , 2010, 24, 2581-2583.	1.0	16
12	UPLC-MS/MS method for the simultaneous quantification of bictegravir and 13 others antiretroviral drugs plus cobicistat and ritonavir boosters in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 181, 113057.	1.4	16
13	High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study. <i>Clinical Infectious Diseases</i> , 2015, 61, 817-825.	2.9	14
14	Switch from Enfuvirtide to Raltegravir Lowers Plasma Concentrations of Darunavir and Tipranavir: a Pharmacokinetic Substudy of the EASIER-ANRS 138 Trial. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3613-3615.	1.4	11
15	Dolutegravir Cerebrospinal Fluid Diffusion in HIV-1-Infected Patients with Central Nervous System Impairment. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz174.	0.4	11
16	Predictive Values of the Human Immunodeficiency Virus Phenotype and Genotype and of Amprenavir and Lopinavir Inhibitory Quotients in Heavily Pretreated Patients on a Ritonavir-Boosted Dual-Protease-Inhibitor Regimen. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1642-1646.	1.4	10
17	Quantification of raltegravir (MK0518) in human plasma by high-performance liquid chromatography with photodiode array detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 456-460.	1.2	10
18	Pharmacokinetics and tissue distribution of tenofovir, emtricitabine and dolutegravir in mice. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1094-1101.	1.3	10

#	ARTICLE	IF	CITATIONS
19	Cerebrospinal fluid exposure to bictegavir/emtricitabine/tenofovir in HIV-1-infected patients with CNS impairment. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3280-3285.	1.3	8
20	Effect of high-dose rifampicin on efavirenz pharmacokinetics: drug-drug interaction randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1250-1258.	1.3	6
21	Telaprevir enhances ribavirin-induced anaemia through renal function impairment. <i>Antiviral Therapy</i> , 2015, 20, 479-486.	0.6	5
22	Population Pharmacokinetic Model of Plasma and Cellular Mycophenolic Acid in Kidney Transplant Patients from the CIMTRE Study. <i>Drugs in R and D</i> , 2020, 20, 331-342.	1.1	5
23	Characteristics of Dolutegravir and Bictegavir Plasma Protein Binding: a First Approach for the Study of Pharmacologic Sanctuaries. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	5
24	Switching to darunavir/ritonavir achieves viral suppression in patients with persistent low replication on first-line lopinavir/ritonavir. <i>Aids</i> , 2008, 22, 2405-2407.	1.0	3
25	Differential pharmacokinetic interaction of cyclosporine and tacrolimus with colchicine in renal allograft recipients. <i>Clinical Transplantation</i> , 2018, 32, e13405.	0.8	3
26	External Validation of the Bilirubin-Atazanavir Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected Patients. <i>AAPS Journal</i> , 2013, 15, 308-315.	2.2	2
27	Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7903-7905.	1.4	2
28	Reply to comment on "pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients". <i>Aids</i> , 2011, 25, 1011-1012.	1.0	0
29	Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV-hepatitis C virus coinfecting patients treated with boceprevir or telaprevir-based therapy. <i>Aids</i> , 2016, 30, 2085-2090.	1.0	0
30	Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1555-1563.	0.8	0